Valar AI
Valar AI
AI-driven diagnostics company predicting cancer treatment response from pathology slides.
About
Valar Labs develops AI-powered diagnostics that analyze pathology slides to predict cancer treatment response. Their technology, exemplified by the Vesta platform for bladder cancer, aims to reduce uncertainty in treatment decisions and personalize care for patients. The company collaborates with healthcare providers and pharmaceutical companies to advance precision oncology.
Key facts
At-a-glance profile data
- Website
- valar.com
- Headquarters
- Israel
- Founded
- 2010
- Employees
- 28
- Total funding
- $26M (Series A)
- Business model
- B2B
- Tags
- FintechVenture CapitalPaymentsDigital PaymentsFinancial Services
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 30 May 2024 | Series A | $22M | DCVC, Matt Bornstein |
| 1 Apr 2022 | Seed Round | $4M | Matt Bornstein |
Tech stack
Detected on valar.com, last scanned 22 Sept 2026. Run your own scan
- Frontend
- Next.js
- CDN
- Vercel
- Email provider
- Google Workspace
- Video / media
- Vimeo
Add first review
Frequently asked
How much funding has Valar AI raised?
Valar AI has raised a total of $26M in funding. The most recent round on record is Series A.
How many employees does Valar AI have?
Valar AI has approximately 28 people on record.